Source: International Congress 2019 – Clinical studies of asthma treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jackson (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), J. Kavanagh (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom). The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks. 2547

Member's Comments

No comment yet.

Related content which might interest you: Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Real life benralizumab effect in patients with severe eosinophilic asthma after 16 weeks of observation Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype Source: International Congress 2016 – Asthma management Year: 2016 Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The clinical, spirometric and cytological profiles of exacerbations in poorly controlled severe persistent asthmatics Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Improved small airway function by benralizumab in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – From respiratory physiology to clinical practice: exercise and respiratory muscles Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011